REFERENCES
1. Llovet JM, Fuster J, Bruix J; Barcelona-Clinic Liver Cancer G. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115-20.
2. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-55.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
6. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006;26:385-90.
7. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110-8.
8. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
9. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003;10:204-9.
10. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79-87.
11. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, et al. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3.
12. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-21.
13. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
14. Lamerz R, Runge M, Stieber P, Meissner E. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res 1999;19:2489-93.
15. Yan L, Chen Y, Zhou J, Zhao H, Zhang H, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int J Infect Dis 2018;67:92-7.
16. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006;26:4713-9.
17. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007;97:1399-403.
18. Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomin A, et al. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol Int 2013;7:1050-7.
19. Park S, Lee EJ, Rim CH, Seong J. Plasma cell-free DNA as a predictive marker after radiotherapy for hepatocellular carcinoma. Yonsei Med J 2018;59:470-9.
20. Zhang C, Li J, Huang T, Duan S, Dai D, et al. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget 2016;7:81255-67.
21. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, et al. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011;91:702-7.
22. Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, et al. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol 2011;91:455-60.
23. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000;6:3516-21.
24. Wei L, Huang Y, Zhao R, Zhang J, Liu Q, et al. Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases. Clin Exp Med 2018;18:79-87.
25. Holmila R, Sklias A, Muller DC, Degli Esposti D, Guilloreau P, et al. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. PLoS One 2017;12:e0174265.
26. Marchio A, Amougou Atsama M, Béré A, Komas NP, Noah Noah D, et al. Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma. Clin Exp Med 2018;18:421-31.
27. Labgaa I, Villacorta-Martin C, D’Avola D, Craig AJ, von Felden J, et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018;37:3740-52.
28. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer 2016;7:1907-14.
29. Ikeda S, Lim JS, Kurzrock R. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: implications for targeted therapeutics. Mol Cancer Ther 2018;17:1114-22.
30. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2014;20:5976-85.
31. Lim HY, Merle P, Weiss KH, Yau T, Ross P, et al. Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma. Clin Cancer Res 2018;24:4650-61.
32. Cai ZX, Chen G, Zeng YY, Dong XQ, Lin MJ, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. Int J Cancer 2017;141:977-85.
33. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007;120:1833-40.
34. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
35. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
36. Thomson JM, Parker JS, Hammond SM. Microarray analysis of miRNA gene expression. Methods Enzymol 2007;427:107-22.
37. Miotto E, Saccenti E, Lupini L, Callegari E, Negrini M, et al. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers Prev 2014;23:2638-42.
38. Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag M, et al. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol 2014;53:208-17.
39. Dingle TC, Sedlak RH, Cook L, Jerome KR. Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances. Clin Chem 2013;59:1670-2.
40. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013;10:1003-5.
41. Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, et al. Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res 2015;3:12.
42. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86.
43. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep 2014;41:4513-9.
44. Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, et al. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep 2015;42:713-20.
45. Qi P, Cheng SQ, Wang H, Li N, Chen YF, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.
46. Xu J, Wu C, Che X, Wang L, Yu D, et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
47. Ge W, Yu DC, Li QG, Chen X, Zhang CY, et al. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab 2014;60:427-34.
48. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167-75.
49. Zhou J, Yu L, Gao X, Hu J, Wang J, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781-8.
50. Zuo D, Chen L, Liu X, Wang X, Xi Q, et al. Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma. Tumour Biol 2016;37:6539-49.
51. Moshiri F, Salvi A, Gramantieri L, Sangiovanni A, Guerriero P, et al. Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 2018;9:15350-64.
52. Zhuang C, Jiang W, Huang D, Xu L, Yang Q, et al. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2016;40:386-96.
53. Xie Y, Yao Q, Butt AM, Guo J, Tian Z, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther 2014;15:1248-55.
54. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012;5:492-7.
55. Zheng XH, Cui C, Zhou XX, Zeng YX, Jia WH. Centrifugation: an important pre-analytic procedure that influences plasma microRNA quantification during blood processing. Chin J Cancer 2013;32:667-72.
56. El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014;6:818-24.
57. Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, et al. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. PLoS One 2015;10:e0141448.
58. Chen S, Chen H, Gao S, Qiu S, Zhou H, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res 2017;47:312-20.
59. Guo X, Lv X, Lv X, Ma Y, Chen L, et al. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget 2017;8:44050-8.
60. Zekri AN, Youssef AS, El-Desouky ED, Ahmed OS, Lotfy MM, et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol 2016;37:12273-86.
61. Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, et al. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081.
62. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 2014;8:819-29.
63. Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, et al. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr) 2012;35:301-8.
64. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014;16:717-27.
65. Su H, Yang JR, Xu T, Huang J, Xu L, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009;69:1135-42.
66. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
67. Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol 2014;31:177.
68. Zhang JP, Zeng C, Xu L, Gong J, Fang JH, et al. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 2014;33:4069-76.
69. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010;52:60-70.
70. Zhang JG, Shi Y, Hong DF, Song M, Huang D, et al. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/beta-catenin pathway. Sci Rep 2015;5:8087.
71. Wang F, Ying H, He B, Pan Y, Sun H, et al. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma. Tumour Biol 2016;37:4945-53.
72. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70-3.
73. Yang L, Xu Q, Xie H, Gu G, Jiang J. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance. Clin Transl Oncol 2016;18:841-7.
74. Qu Z, Wu J, Wu J, Ji A, Qiang G, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:80666-78.
75. Shi M, Jiang Y, Yang L, Yan S, Wang YG, et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J Cell Biochem 2018;119:4711-6.
76. Zheng J, Zhou Z, Xu Z, Li G, Dong P, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. Mol Med Rep 2015;12:1584-90.
77. Liu W, Hu J, Zhou K, Chen F, Wang Z, et al. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. Onco Targets Ther 2017;10:3843-51.
78. Wang H, Hou L, Li A, Duan Y, Gao H, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014;2014:864894.
79. Wang X, Zhang J, Zhou L, Lu P, Zheng ZG, et al. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model. Int J Clin Exp Pathol 2015;8:1466-78.
80. Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, et al. Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer 2018; doi: 10.1002/ijc.31931.
81. Liver EAftSot. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
82. Ng KT, Lo CM, Wong N, Li CX, Qi X, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation. Oncotarget 2016;7:19824-39.
83. European Association for Study of L, European Organisation for R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012;48:599-641.
84. Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, et al. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207.
85. Suehiro T, Miyaaki H, Kanda Y, Shibata H, Honda T, et al. Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. Oncol Lett 2018;16:3267-73.
86. Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization and Prognosis in Patients with Hepatocellular Carcinoma. Cell Physiol Biochem 2015;37:276-83.
87. Liu M, Liu J, Wang L, Wu H, Zhou C, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One 2014;9:e109347.
88. Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, et al. In hepatocellular carcinoma miR-221 modulates Sorafenib resistance through inhibition of caspase-3 mediated apoptosis. Clin Cancer Res 2017; doi: 10.1158/1078-0432.CCR-16-1464.
89. Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T, et al. MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. Liver Cancer 2017;6:113-25.
90. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013;14:699-712.
91. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 2018;19:143-57.
93. Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dinger ME, et al. The regulatory role of long noncoding RNAs in cancer. Cancer Lett 2017;391:12-9.
94. DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res 2017;2:129-36.
95. Lu J, Xie F, Geng L, Shen W, Sui C, et al. Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. Tumour Biol 2015;36:3231-6.
96. Xu H, Chen Y, Dong X, Wang X. Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2018;27:710-6.
97. Gao S, Xu X, Wang Y, Zhang W, Wang X. Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma. Mol Med Rep 2018;18:3305-13.
98. Luo P, Liang C, Zhang X, Liu X, Wang Y, et al. Identification of long non-coding RNA ZFAS1 as a novel biomarker for diagnosis of HCC. Biosci Rep 2018;38.
99. Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, et al. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res 2016;168:134-45.
100. Yu J, Han J, Zhang J, Li G, Liu H, et al. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine (Baltimore) 2016;95:e4436.
101. Ma W, Wang H, Jing W, Zhou F, Chang L, et al. Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2017;41:163-70.
102. Wang ZF, Hu R, Pang JM, Zhang GZ, Yan W, et al. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett 2018;16:1593-601.
103. Zheng ZK, Pang C, Yang Y, Duan Q, Zhang J, et al. Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Int Med Res 2018;46:348-56.
104. Li J, Wang X, Tang J, Jiang R, Zhang W, et al. HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma. Cell Physiol Biochem 2015;37:687-96.
105. Ma X, Wang X, Yang C, Wang Z, Han B, et al. DANCR Acts as a Diagnostic Biomarker and Promotes Tumor Growth and Metastasis in Hepatocellular Carcinoma. Anticancer Res 2016;36:6389-98.
106. Li J, Gao J, Kan A, Hao T, Huang L. SNHG and UCA1 as prognostic molecular biomarkers in hepatocellular carcinoma: recent research and meta-analysis. Minerva Med 2017;108:568-74.
107. Xie Z, Zhou F, Yang Y, Li L, Lei Y, et al. Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. EBioMedicine 2018;33:57-67.
108. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
109. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63.
110. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011;83:8604-10.
111. Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi MV, et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 2015;6:14545-55.
112. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 2015;61:56-63.
113. Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer 2016;5:128-38.
114. Chen K, Zhang H, Zhang LN, Ju SQ, Qi J, et al. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol 2013;19:3143-9.
115. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, et al. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol 2006;12:3911-4.
116. Iyer P, Zekri AR, Hung CW, Schiefelbein E, Ismail K, et al. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 2010;88:107-11.
117. Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, et al. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine 2018;30:138-47.
118. Hu N, Fan XP, Fan YC, Chen LY, Qiao CY, et al. Hypomethylated Ubiquitin-Conjugating Enzyme2 Q1 (UBE2Q1) Gene Promoter in the Serum Is a Promising Biomarker for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Tohoku J Exp Med 2017;242:93-100.
119. Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatol Commun 2018;2:718-31.
120. Liao W, Yang H, Xu H, Wang Y, Ge P, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 2016;7:40481-90.
121. Garcia-Fernandez N, Macher HC, Rubio A, Jimenez-Arriscado P, Bernal-Bellido C, et al. Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence. Adv Exp Med Biol 2016;924:25-8.
122. Xu H, Zhu X, Xu Z, Hu Y, Bo S, et al. Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing. J Cancer 2015;6:247-53.
123. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24.
124. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012;2:e000825.
125. Zhu HT, Hasan AM, Liu RB, Zhang ZC, Zhang X, et al. Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma. Oncotarget 2016;7:45637-48.
126. Fu Y, Wei X, Tang C, Li J, Liu R, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett 2013;6:1811-5.
127. Sohn W, Kim J, Kang SH, Yang SR, Cho JY, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med 2015;47:e184.
128. Huang JT, Liu SM, Ma H, Yang Y, Zhang X, et al. Systematic Review and Meta-Analysis: Circulating miRNAs for Diagnosis of Hepatocellular Carcinoma. J Cell Physiol 2016;231:328-35.
129. Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer 2016;138:714-20.
130. Luo J, Chen M, Huang H, Yuan T, Zhang M, et al. Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther 2013;6:577-83.
131. Fang T, Lv H, Lv G, Li T, Wang C, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun 2018;9:191.
132. Zhang J, Lin H, Wang XY, Zhang DQ, Chen JX, et al. Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma. Cancer Biomark 2017;19:257-62.
133. Zhao Q, Sun X, Liu C, Li T, Cui J, et al. Expression of the microRNA-143/145 cluster is decreased in hepatitis B virus-associated hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with chronic hepatitis B. Oncol Lett 2018;15:6115-22.
134. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:355-60.
135. Chen L, Chu F, Cao Y, Shao J, Wang F. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. Tumour Biol 2015;36:7439-47.
136. Amr KS, Ezzat WM, Elhosary YA, Hegazy AE, Fahim HH, et al. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene 2016;575:66-70.
137. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011;6:e26971.
138. Li F, Wang F, Zhu C, Wei Q, Zhang T, et al. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Int J Nanomedicine 2018;13:2295-307.
139. Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, et al. Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma. Am J Pathol 2016;186:242-7.
140. Okajima W, Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, et al. Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget 2016;7:53820-36.
141. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015;16:804-15.
142. Gui J, Tian Y, Wen X, Zhang W, Zhang P, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011;120:183-93.
143. Chen Y, Dong X, Yu D, Wang X. Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Int J Clin Exp Med 2015;8:18462-8.
144. Zheng F, Liao YJ, Cai MY, Liu TH, Chen SP, et al. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genet 2015;11:e1004873.
145. Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol 2015;36:4773-6.
146. Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int 2015;2015:731781.
147. Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH, et al. High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clin Biochem 2015;48:1073-8.
148. Kim SS, Cho HJ, Nam JS, Kim HJ, Kang DR, et al. Plasma MicroRNA-21, 26a, and 29a-3p as predictive markers for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Korean Med Sci 2018;33:e6.
149. Cho HJ, Kim SS, Nam JS, Kim JK, Lee JH, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment. Clin Res Hepatol Gastroenterol 2017;41:181-9.
150. Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J, et al. MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. Oncotarget 2016;7:87246-56.
151. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 2015;112:532-8.
152. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids 2015;4:e233.
153. El-Tawdi AH, Matboli M, Shehata HH, Tash F, El-Khazragy N, et al. Evaluation of circulatory RNA-based biomarker panel in hepatocellular carcinoma. Mol Diagn Ther 2016;20:265-77.
154. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int 2013;2013:136106.
155. El-Tawdi AH, Matboli M, El-Nakeep S, Azazy AE, Abdel-Rahman O. Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:869-77.
156. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, et al. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis 2014;5:e1549.
157. Wang X, Zhang W, Tang J, Huang R, Li J, et al. LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. Cell Death Dis 2016;7:e2130.
158. Tang J, Jiang R, Deng L, Zhang X, Wang K, et al. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. Oncotarget 2015;6:4505-15.
159. Konishi H, Ichikawa D, Yamamoto Y, Arita T, Shoda K, et al. Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Sci 2016;107:149-54.
160. Jing W, Gao S, Zhu M, Luo P, Jing X, et al. Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma. Oncol Rep 2016;36:1085-92.
